Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome.

Pyfferoen L, Brabants E, Everaert C, De Cabooter N, Heyns K, Deswarte K, Vanheerswynghels M, De Prijck S, Waegemans G, Dullaers M, Hammad H, De Wever O, Mestdagh P, Vandesompele J, Lambrecht BN, Vermaelen KY.

Oncoimmunology. 2016 Nov 8;6(1):e1253655. doi: 10.1080/2162402X.2016.1253655. eCollection 2016 Nov 8.

PMID:
28197369
2.

Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation.

Van Gorp H, Saavedra PH, de Vasconcelos NM, Van Opdenbosch N, Vande Walle L, Matusiak M, Prencipe G, Insalaco A, Van Hauwermeiren F, Demon D, Bogaert DJ, Dullaers M, De Baere E, Hochepied T, Dehoorne J, Vermaelen KY, Haerynck F, De Benedetti F, Lamkanfi M.

Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14384-14389. Epub 2016 Nov 22.

PMID:
27911804
3.

The immunophenotypic fingerprint of patients with primary antibody deficiencies is partially present in their asymptomatic first-degree relatives.

Bogaert DJ, De Bruyne M, Debacker V, Depuydt P, De Preter K, Bonroy C, Philippé J, Bordon V, Lambrecht BN, Kerre T, Cerutti A, Vermaelen KY, Haerynck F, Dullaers M.

Haematologica. 2017 Jan;102(1):192-202. doi: 10.3324/haematol.2016.149112. Epub 2016 Sep 15.

PMID:
27634199
4.

Using a bronchial airway gene expression classifier.

Vermaelen K, Brusselle GG.

Lancet Respir Med. 2016 Sep;4(9):694. doi: 10.1016/S2213-2600(16)30239-9. No abstract available.

PMID:
27599245
5.

Genes associated with common variable immunodeficiency: one diagnosis to rule them all?

Bogaert DJ, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F.

J Med Genet. 2016 Sep;53(9):575-90. doi: 10.1136/jmedgenet-2015-103690. Epub 2016 Jun 1. Review.

PMID:
27250108
6.

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy.

De Wolf K, Vermaelen K, De Meerleer G, Lambrecht BN, Ost P.

Oncoimmunology. 2015 May 27;4(10):e1042198. eCollection 2015 May 27. Review.

PMID:
26464810
7.

Rehabilitation in patients with radically treated respiratory cancer: A randomised controlled trial comparing two training modalities.

Salhi B, Haenebalcke C, Perez-Bogerd S, Nguyen MD, Ninane V, Malfait TL, Vermaelen KY, Surmont VF, Van Maele G, Colman R, Derom E, van Meerbeeck JP.

Lung Cancer. 2015 Aug;89(2):167-74. doi: 10.1016/j.lungcan.2015.05.013. Epub 2015 May 22.

PMID:
26051445
8.

Non-coding RNAs and respiratory disease.

Mestdagh P, Vandesompele J, Brusselle G, Vermaelen K.

Thorax. 2015 Apr;70(4):388-90. doi: 10.1136/thoraxjnl-2014-206404. Epub 2014 Nov 5. Review.

PMID:
25378544
9.

The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling.

Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, Bracke M, De Wever O, Hendrix A.

J Extracell Vesicles. 2014 Sep 18;3. doi: 10.3402/jev.v3.24858. eCollection 2014 Sep 18.

PMID:
25317274
10.

Lung tumours reprogram pulmonary dendritic cell immunogenicity at the microRNA level.

Pyfferoen L, Mestdagh P, Vergote K, De Cabooter N, Vandesompele J, Lambrecht BN, Vermaelen KY.

Int J Cancer. 2014 Dec 15;135(12):2868-77. doi: 10.1002/ijc.28945. Epub 2014 May 14.

PMID:
24789737
11.

Contribution of four common pulmonary function tests to diagnosis of patients with respiratory symptoms: a prospective cohort study.

Decramer M, Janssens W, Derom E, Joos G, Ninane V, Deman R, Van Renterghem D, Liistro G, Bogaerts K; Belgian Pulmonary Function Study Investigators..

Lancet Respir Med. 2013 Nov;1(9):705-13. doi: 10.1016/S2213-2600(13)70184-X. Epub 2013 Oct 4.

PMID:
24429274
12.

Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer.

Vermaelen K, Brusselle G.

Pulm Pharmacol Ther. 2013 Oct;26(5):544-54. doi: 10.1016/j.pupt.2013.05.003. Epub 2013 May 21. Review.

PMID:
23701918
13.

Expressed wishes and incidence of euthanasia in advanced lung cancer patients.

Pardon K, Deschepper R, Vander Stichele R, Bernheim JL, Mortier F, Schallier D, Germonpré P, Galdermans D, Van Kerckhoven W, Deliens L; EOLIC-consortium..

Eur Respir J. 2012 Oct;40(4):949-56. Epub 2012 Apr 20.

PMID:
22523361
14.

Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients.

Pardon K, Deschepper R, Vander Stichele R, Bernheim JL, Mortier F, Bossuyt N, Schallier D, Germonpré P, Galdermans D, Van Kerckhoven W, Deliens L; EOLIC-consortium..

Support Care Cancer. 2012 Oct;20(10):2473-82. Epub 2012 Jan 15.

PMID:
22246616
15.

Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.

Speeckaert R, van Geel N, Luiten RM, van Gele M, Speeckaert M, Lambert J, Vermaelen K, Tjin EP, Brochez L.

Anticancer Res. 2011 Nov;31(11):3697-703.

PMID:
22110189
16.

Preferred and actual involvement of advanced lung cancer patients and their families in end-of-life decision making: a multicenter study in 13 hospitals in Flanders, Belgium.

Pardon K, Deschepper R, Vander Stichele R, Bernheim JL, Mortier F, Schallier D, Germonpré P, Galdermans D, Kerckhoven WV, Deliens L; End-of-Life Information and Communication Consortium..

J Pain Symptom Manage. 2012 Mar;43(3):515-26. doi: 10.1016/j.jpainsymman.2011.04.008. Epub 2011 Nov 1.

PMID:
22048004
17.

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.

Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M, van Gele M, Thielemans K, Neyns B, Roche N, Verbeke N, Deron P, Speeckaert M, Brochez L.

Eur J Cancer. 2012 Sep;48(13):2004-11. doi: 10.1016/j.ejca.2011.09.007. Epub 2011 Oct 25.

PMID:
22033321
18.

[Medication review in the elderly by the community pharmacist: a pilot study].

De Wulf I, Depuydt C, Develter M, De Waele L, Leyssens A, Pierreux T, Vansteenkiste D, Vermaelen K, Vermeir S, Foulon V.

J Pharm Belg. 2010 Dec;(4):110-7. French. No abstract available.

PMID:
21294317
19.

Investigational approaches for mesothelioma.

Surmont VF, van Thiel ER, Vermaelen K, van Meerbeeck JP.

Front Oncol. 2011 Aug 22;1:22. doi: 10.3389/fonc.2011.00022. eCollection 2011 Aug 22.

PMID:
22666659
20.

Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.

Speeckaert R, van Geel N, Vermaelen KV, Lambert J, Van Gele M, Speeckaert MM, Brochez L.

Pigment Cell Melanoma Res. 2011 Apr;24(2):334-44. doi: 10.1111/j.1755-148X.2010.00799.x. Epub 2010 Nov 19. Review.

PMID:
21029398

Supplemental Content

Loading ...
Support Center